WO2002026716A3 - Benzimidazoles and methods for use thereof in the treatment of cancer or viral infections - Google Patents

Benzimidazoles and methods for use thereof in the treatment of cancer or viral infections Download PDF

Info

Publication number
WO2002026716A3
WO2002026716A3 PCT/US2001/029261 US0129261W WO0226716A3 WO 2002026716 A3 WO2002026716 A3 WO 2002026716A3 US 0129261 W US0129261 W US 0129261W WO 0226716 A3 WO0226716 A3 WO 0226716A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
methods
viral infections
benzimidazoles
cancer
Prior art date
Application number
PCT/US2001/029261
Other languages
French (fr)
Other versions
WO2002026716A2 (en
Inventor
James C Quada Jr
Joseph K Agyin
James Berger Camden
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/670,168 external-priority patent/US6462062B1/en
Priority claimed from US09/670,170 external-priority patent/US6380232B1/en
Priority claimed from US09/670,166 external-priority patent/US6608096B1/en
Priority claimed from US09/670,169 external-priority patent/US6407105B1/en
Priority to MXPA03002601A priority Critical patent/MXPA03002601A/en
Priority to EP01973190A priority patent/EP1330441A2/en
Priority to AU9279601A priority patent/AU9279601A/en
Priority to AU2001292796A priority patent/AU2001292796B2/en
Application filed by Procter & Gamble filed Critical Procter & Gamble
Priority to CA002422916A priority patent/CA2422916A1/en
Priority to JP2002531100A priority patent/JP2004509949A/en
Publication of WO2002026716A2 publication Critical patent/WO2002026716A2/en
Publication of WO2002026716A3 publication Critical patent/WO2002026716A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C07D235/32—Benzimidazole-2-carbamic acids, unsubstituted or substituted; Esters thereof; Thio-analogues thereof

Abstract

Benzimidole derivatives of structures (I, II and III) in which R is CO2R2 or CONHR2 and the substituents have the meaning given in the description and salts and prodrugs thereof are disclosed, together with methods for the treatment of cancers or viral infections in warm blooded animals by administration of these compounds. such compounds may be used in combination with a chemotherapeutic agent and/or a potentiator.
PCT/US2001/029261 2000-09-26 2001-09-19 Benzimidazoles and methods for use thereof in the treatment of cancer or viral infections WO2002026716A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2002531100A JP2004509949A (en) 2000-09-26 2001-09-19 Compounds and methods for their use in treating cancer or viral infections
CA002422916A CA2422916A1 (en) 2000-09-26 2001-09-19 Compounds and methods for use thereof in the treatment of cancer or viral infections
MXPA03002601A MXPA03002601A (en) 2000-09-26 2001-09-19 Benzimidazoles and methods for use thereof in the treatment of cancer or viral infections.
AU2001292796A AU2001292796B2 (en) 2000-09-26 2001-09-19 Benzimidazoles and methods for use thereof in the treatment of cancer or viral infections
EP01973190A EP1330441A2 (en) 2000-09-26 2001-09-19 Benzimidazoles and methods for use thereof in the treatment of cancer or viral infections
AU9279601A AU9279601A (en) 2000-09-26 2001-09-19 Compounds and methods for use thereof in the treatment of cancer or viral infections

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US09/670,170 2000-09-26
US09/670,168 US6462062B1 (en) 2000-09-26 2000-09-26 Compounds and methods for use thereof in the treatment of cancer or viral infections
US09/670,168 2000-09-26
US09/670,169 US6407105B1 (en) 2000-09-26 2000-09-26 Compounds and methods for use thereof in the treatment of cancer or viral infections
US09/670,166 US6608096B1 (en) 2000-09-26 2000-09-26 Compounds and methods for use thereof in the treatment of cancer or viral infections
US09/670,170 US6380232B1 (en) 2000-09-26 2000-09-26 Benzimidazole urea derivatives, and pharmaceutical compositions and unit dosages thereof
US09/670,169 2000-09-26
US09/670,166 2000-09-26

Publications (2)

Publication Number Publication Date
WO2002026716A2 WO2002026716A2 (en) 2002-04-04
WO2002026716A3 true WO2002026716A3 (en) 2002-07-11

Family

ID=27505337

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/029261 WO2002026716A2 (en) 2000-09-26 2001-09-19 Benzimidazoles and methods for use thereof in the treatment of cancer or viral infections

Country Status (6)

Country Link
EP (1) EP1330441A2 (en)
JP (1) JP2004509949A (en)
AU (2) AU2001292796B2 (en)
CA (1) CA2422916A1 (en)
MX (1) MXPA03002601A (en)
WO (1) WO2002026716A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1317442T3 (en) 2000-09-11 2006-02-13 Chiron Corp Quinolinone derivatives as tyrosine kinase inhibitors
US6380232B1 (en) 2000-09-26 2002-04-30 The Procter & Gamble Company Benzimidazole urea derivatives, and pharmaceutical compositions and unit dosages thereof
US20030144312A1 (en) * 2001-10-30 2003-07-31 Schoenhard Grant L. Inhibitors of ABC drug transporters in multidrug resistant cancer cells
JP2005521712A (en) 2002-03-26 2005-07-21 アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナ Solubilization of weak bases
US7205412B2 (en) * 2002-07-03 2007-04-17 Samsung Electronics Co., Ltd. Antibiotic additive and ink composition comprising the same
KR20050037585A (en) 2002-08-23 2005-04-22 카이론 코포레이션 Benzimidazole quinolinones and uses thereof
JP2004115397A (en) * 2002-09-25 2004-04-15 Fuji Photo Film Co Ltd Liposome comprising therapeutic agent for vascular disease
MXPA06011420A (en) * 2004-04-01 2007-04-20 Cardiome Pharma Corp Derivatives of ion channel modulating compounds and pharmaceutical compositions and uses thereof.
ATE530533T1 (en) 2005-05-17 2011-11-15 Novartis Ag METHOD FOR SYNTHESIS OF HETEROCYCLIC COMPOUNDS
JP5657566B2 (en) * 2008-12-24 2015-01-21 バイアル ポルテラ アンド シーエイ エス エイＢＩＡＬ−Ｐｏｒｔｅｌａ ＆ Ｃａ， Ｓ．Ａ． Medicine
KR101064258B1 (en) * 2008-12-29 2011-09-14 한국과학기술연구원 Benzoarylureido compounds, and composition for prevention or treatment of neurodegenerative disease containing the same
CN103450093A (en) * 2013-09-06 2013-12-18 中国药科大学 2-aminobenzimidazoles and applications thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3399212A (en) * 1966-05-16 1968-08-27 Smith Kline French Lab Benzimidazole ureas
US3480642A (en) * 1967-03-22 1969-11-25 Smithkline Corp Process for producing 2-carbalkoxyaminobenzimidazoles
GB1397886A (en) * 1972-10-31 1975-06-18 Bayer Ag Benzimidazoles and their use as fungicides and bactericides
US5767138A (en) * 1995-04-12 1998-06-16 Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
WO1998051303A1 (en) * 1997-05-16 1998-11-19 The Procter & Gamble Company Hiv and cancer treatment

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU177582B (en) * 1977-10-25 1981-11-28 Chinoin Gyogyszer Es Vegyeszet Fungicide preparations containing new benzimidazole derivatives and process for preparing the active materials thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3399212A (en) * 1966-05-16 1968-08-27 Smith Kline French Lab Benzimidazole ureas
US3480642A (en) * 1967-03-22 1969-11-25 Smithkline Corp Process for producing 2-carbalkoxyaminobenzimidazoles
GB1397886A (en) * 1972-10-31 1975-06-18 Bayer Ag Benzimidazoles and their use as fungicides and bactericides
US5767138A (en) * 1995-04-12 1998-06-16 Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
WO1998051303A1 (en) * 1997-05-16 1998-11-19 The Procter & Gamble Company Hiv and cancer treatment

Also Published As

Publication number Publication date
MXPA03002601A (en) 2005-02-25
AU2001292796B2 (en) 2005-12-22
WO2002026716A2 (en) 2002-04-04
JP2004509949A (en) 2004-04-02
EP1330441A2 (en) 2003-07-30
CA2422916A1 (en) 2002-04-04
AU9279601A (en) 2002-04-08

Similar Documents

Publication Publication Date Title
TR200200717T2 (en) Therapeutic quinazoline derivatives.
WO2002026716A3 (en) Benzimidazoles and methods for use thereof in the treatment of cancer or viral infections
HK1081948A1 (en) Quinolinyl-pyrrolopyrazoles
LU92745I2 (en) Netupitant / Palonosetron and their pharmaceutically acceptable derivatives (AKYNZEOr)
PL377821A1 (en) 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer
NO20014662L (en) Methods and Preparations for Treating Solid Tumors
WO2005023759A3 (en) Heterocyclic inhibitors of mek and methods of use thereof
WO2006034341A3 (en) Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
IT1311924B1 (en) PHARMACEUTICAL COMPOUNDS.
HK1096399A1 (en) P-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same p-
ATE456952T1 (en) SOLUBLE TOPOISOMERASE POISONS
EP1177791A3 (en) Use of glycogen phosphorylase inhibitors to inhibit tumor growth
DK1278518T3 (en) Synergistic combination for the treatment of colorectal cancer
EE200000472A (en) Antineoplastic agents
DK1313740T3 (en) Prodrugs of imidazopyridine derivatives
ATE406155T1 (en) TRIPTOLIDE PRODRUGS FOR CANCER THERAPY
AU2001234089A1 (en) Cancer remedy comprising anthranilic acid derivative as active ingredient
AU3408901A (en) Cancer remedy comprising anthranilic acid derivative as active ingredient
GEP20074058B (en) 4-(7-halo-2-quino(xa) linyloxy-phenoxy-propionic acid derivatives as antineoplastic agents
EP1109560A4 (en) Compounds useful as aicarft inhibitors
ATE390923T1 (en) TOPOISOMERASE TOXICANTS
ATE424200T1 (en) SOLUBILIZED TOPOISOMERASE POISON AGENT
PT1150704E (en) MELAGATRAN FOR THE TREATMENT OF INFLAMMATION
AU3913900A (en) Radioenhanced cancer treatment using orally administered camptothecin derivatives
EA200300427A1 (en) ANTI-TUMOR THERAPY, INCLUDING DERIVATAMIC DERIVATIVES

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2422916

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/002601

Country of ref document: MX

Ref document number: 442/DELNP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2002531100

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2001973190

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2001292796

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2001973190

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 2001292796

Country of ref document: AU